These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36710490)

  • 21. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
    Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
    Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.
    Zhang C; Wang J; Wang X; Meng Z; Cheng Y; Li K
    Cancer Biol Med; 2021 Jul; 19(8):1249-58. PubMed ID: 34302324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial.
    Wang Q; Li Z; Guo J; Li W; You F
    PLoS One; 2022; 17(12):e0275058. PubMed ID: 36525406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial.
    Zheng X; Wang W; Wang G; Liu S
    Medicine (Baltimore); 2021 Jul; 100(28):e25002. PubMed ID: 34260519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial.
    Zhou Y; Zhao B; Wu W; Yang X; Long S; Deng H; He W; Liao G; Li Q; Xie Z
    Trials; 2018 Sep; 19(1):474. PubMed ID: 30180874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB-IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial.
    Lin J; Yang T; Chen W; Qi X; Cao Y; Zheng X; Chen H; Sun L; Lin L
    J Thorac Dis; 2022 Nov; 14(11):4560-4570. PubMed ID: 36524089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
    Zhou C; Wang Z; Sun Y; Cao L; Ma Z; Wu R; Yu Y; Yao W; Chang J; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Wang J; Li P; Qin M; Lu D; Yang J
    Lancet Oncol; 2022 Feb; 23(2):220-233. PubMed ID: 35038432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant).
    Park SJ; Kang HJ; Jun HJ; Shin SH; Yoo HS
    Medicine (Baltimore); 2020 Jan; 99(4):e18735. PubMed ID: 31977865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
    Paz-Ares LG; Altug S; Vaury AT; Jaime JC; Russo F; Visseren-Grul C
    BMC Cancer; 2010 Mar; 10():85. PubMed ID: 20211022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
    Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
    J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
    Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
    Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer.
    Zhang W; Wang J; Wang Q; Cheng Y; Yang L; Li Y; Zhong H; Chu T; Dong Y; Zhang Y; Qian F; Xiong L; Shi C; Zhang C; He Z; Zhu J; Liu X; Ma H; Li K; Han B
    Lung Cancer; 2023 Oct; 184():107353. PubMed ID: 37647728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of Chinese herbal medicine Shen-Qi Hua-Yu formula in patients with diabetic lower extremity artery disease: Study protocol of a multi-center, randomized, double-blind, placebo-controlled trial.
    Leng Y; Gao H; Fu X; Xie H; Hu Z; Zhu J; Liu X; Zhou X; Xie Z; Xie C
    Medicine (Baltimore); 2020 Jan; 99(3):e18713. PubMed ID: 32011447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
    Zhong H; Sun S; Chen J; Wang Z; Zhao Y; Zhang G; Chen G; Zhou M; Zhou J; Du Y; Wu L; Xu Z; Mei X; Zhang W; He J; Cui J; Zhang Z; Luo H; Liu W; Sun M; Wu J; Shen Y; Zhang S; Yang N; Wang M; Lu J; Li K; Yao W; Sun Q; Yue H; Wang L; Ye S; Li B; Zhuang X; Pan Y; Zhang M; Shu Y; He Z; Pan L; Ling Y; Liu S; Zhang Q; Jiao S; Han B
    Lancet Respir Med; 2024 May; 12(5):355-365. PubMed ID: 38309287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
    Xu L; Li H; Xu Z; Wang Z; Liu L; Tian J; Sun J; Zhou L; Yao Y; Jiao L; Su W; Guo H; Chen P; Liu J
    BMC Complement Altern Med; 2012 Aug; 12():112. PubMed ID: 22853619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: protocol for a randomized double-blind controlled trial.
    Zhou ZY; Xu L; Li HG; Tian JH; Jiao LJ; You SF; Han ZF; Jiang Y; Guo HR; Liu H
    J Integr Med; 2014 May; 12(3):175-81. PubMed ID: 24861837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yu G; Shen Y; Xu X; Zhong F
    PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
    Shen Z; Zheng K; Zou J; Gu P; Xing J; Zhang L; Zhu L; Shen H
    Trials; 2021 Jan; 22(1):55. PubMed ID: 33441157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.